EUCTR2007-006305-25-SE进行中（未招募）不适用
Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome
Karolinska University Hospital0 个研究点开始时间: 2008年1月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Genetically verified Prader-Willi syndrome diagnosis
- •Age between 18 and 50 years
- •Patients that have signed informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Serious depression
- •Increased liver enzymes (ASAT or ALAT >2.5 normal range)
- •Pregnant or lactating women
- •Medication with antidepressants
- •Medication inhibiting CYP3A
- •Significant reduction in kidney function
- •Patients with epilepsia
研究者
相似试验
进行中（未招募）
不适用
The impact of Rimonabant in overweight women with prior gestational diabetes - RIGDEUCTR2007-000907-13-ATMUW, Innere Med III, Abt.für Endokrinologie & Stoffwechsel
进行中（未招募）
不适用
Effects of Rimonabant on Liver Fat, Visceral Adipose Tissue Mass and early Markers of CardioDiabetes in obese Subjects with the Metabolic Syndrome – a randomized, double-blind clinical trialoverweight, obesityMedDRA version: 9.1Level: PTClassification code 10033307Term: OverweightEUCTR2007-000775-42-DEniversity Hospital Tübingen
终止
4 期
The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body CompositionObesityNCT00584389University of Surrey14
已完成
3 期
VIsceral Fat Reduction Assessed by CT-scan On RImonabAntMetabolic SyndromeNCT00299325Sanofi254
已完成
3 期
Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese PatientsEating DisordersObesityNCT00481975Sanofi289